Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 5/20 | 0.73 |
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406423 | 1.00 | SNCA (0.73) | SNCABCHEMAPTLMNASMN1; SMN2 | |
| SCHEMBL17999732 | 0.86 | SNCA (0.84) | SNCABCHEMAPTLMNASMN1; SMN2 | |
| SCHEMBL17999733 | 0.86 | SNCA (0.84) | SNCABCHEMAPTLMNASMN1; SMN2 | |
| SCHEMBL21751995 | 0.85 | SNCA (1.00) | SNCABCHEMAPTLMNASMN1; SMN2 | |
| SCHEMBL30858752 | 0.81 | BCHE (0.54) | SNCABCHEMAPTALDH1A1KDM4E | |
| SCHEMBL29406451 | 0.81 | SNCA (0.60) | SNCABCHEMAPTALDH1A1KDM4E | |
| SCHEMBL19918106 | 0.81 | SNCA (0.60) | SNCABCHEMAPTALDH1A1KDM4E | |
| SCHEMBL30858755 | 0.81 | BCHE (0.54) | SNCABCHEMAPTALDH1A1KDM4E | |
| SCHEMBL31425263 | 0.78 | BCHE (0.53) | SNCABCHEMAPTLMNASMN1; SMN2 | |
| SCHEMBL19942820 | 0.77 | BCHE (0.49) | SNCABCHEMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-09-21 | — | — | US | disclosed |
| US-11560360-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200407333-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-12-31 | — | — | US | disclosed |
| US-10745366-B2 | Therapeutic compounds | ARIZON BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190185441-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-20 | — | — | US | disclosed |
| US-20180065941-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2018039487-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065941-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | GSR, COQ8A, TXNRD2 | SNCA 766/4885BCHE 2853/4885MAPT 634/4885 |
| US-20200407333-A1 | THERAPEUTIC COMPOUNDS | CFTR, MC2R, RPS21 | SNCA 1861/4885BCHE 2894/4885MAPT 2395/4885 |
| US-11560360-B2 | Therapeutic compounds | CFTR, MC2R, RPS21 | SNCA 1861/4885BCHE 2894/4885MAPT 2395/4885 |
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | CFTR, C1R, FURIN | SNCA 2990/4885BCHE 1829/4885MAPT 1136/4885 |
| US-20190185441-A1 | THERAPEUTIC COMPOUNDS | CFTR, C1R, FURIN | SNCA 2990/4885BCHE 1829/4885MAPT 1136/4885 |
| US-10745366-B2 | Therapeutic compounds | CFTR, C1R, FURIN | SNCA 2990/4885BCHE 1829/4885MAPT 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.